FarshchianART
18.12.2023 16:02:55 CET | ACCESS Newswire | Press release
MIAMI, FL / ACCESSWIRE / December 18, 2023 / Mahmoud Farshchian, 93, the renowned Iranian artist, continues to captivate art enthusiasts with his exceptional talent and artistic vision. FarshchianART -- a foundation created by the Farschian family and dedicated to collecting, exhibiting, preserving, and interpreting the art and archives of Mahmoud Farshchian -- has announced that one of his paintings inspired by the original "Fifth Day of Creation" fetched an impressive price of $120,000 at a prestigious auction held at Sotheby's. This sale highlights the enduring appeal and value of Farshchian's works in the art market.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Image of Painter
"Fifth Day Of Creation" - 6x4 feet - circa 1980s - estimated at 1.8 million USD, captured the adoration of collector Stuart Cary Welch. He commissioned Farshchian, who painted an inspired painting of 3x2 feet.
When Welch saw Farshchian's collection, he stated: "Once experienced, Farshchian's pictures tend to linger in our minds, revealing new facets…. Through his enticing, sometimes upsetting worlds, Farshchian's brush dances to the rhythms of traditional vegetal arabesques."
-- DR. STUART CARY WELCH, Curator - Harvard University Art Museums, 1970-1995
Mahmoud Farshchian, who is currently 94 years old and residing in Englewood Cliffs, NJ, has been recognized as a master of Persian miniature painting for several decades. His unique style, blending traditional Persian elements with contemporary influences, has garnered international acclaim. With a career spanning over six decades, Farshchian's artworks have become highly sought after by collectors and art enthusiasts worldwide.
Leila Farshchian, the director of Farshchianart.com, expressed her delight at the auction result, stating, "We are thrilled to witness the continued appreciation of my father's work in the art world. The sale of the inspired commissioned 'Fifth Day of Creation' for $120,000 reaffirms the enduring value of Mahmoud Farshchian's artistic legacy. His ability to evoke profound emotions through his brushstrokes is truly remarkable."
It is worth noting that Farshchian's paintings have achieved even higher prices in the United States, with some reaching up to $1,800,000. The artist's ability to capture the essence of Persian culture, history, and spirituality has resonated deeply with collectors, establishing Farshchian as an icon of Persian art.
For more information about Mahmoud Farshchian and his extraordinary artworks, please visit Farshchianart.com.
###
About Mahmoud Farshchian:
Mahmoud Farshchian is a renowned Iranian artist known for his mastery of Persian miniature painting. With a career spanning over six decades, Farshchian's works have been exhibited and collected in prestigious galleries and museums worldwide. His unique artistic style combines traditional Persian techniques with contemporary influences, creating captivating and evocative compositions.
Media Contact: https://www.farshchianart.com
Contact Information
Leila Farshchian
Director
leila@farshchianart.com
201-777-4557
Related Images
SOURCE: FarshchianART
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom